NCT00437476View on ClinicalTrials.gov

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

PHASE3UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
HIV InfectionsHepatitis C
Interventions
DRUG

LPV/r

Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)

DRUG

Nucleoside Reverse Transcriptase Inhibitors

NRTIs for 26 weeks (A) or 24 weeks (B)

DRUG

PEG-IFNa 2a

PEG-IFNa 2a 180 mcg/week (48 weeks)

DRUG

Ribavirin

Ribavirin 1-1.2 g/day (48 weeks)

Trial Locations (1)

20127

RECRUITING

San Raffaele Hospital Dep. Infectious Diseases, Milan

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

lead

IRCCS San Raffaele

OTHER

NCT00437476 - Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy | Biotech Hunter | Biotech Hunter